This review demonstrates the impact of mesenchymal stem cells on ovarian function in premature ovarian insufficiency, highlighting their regenerative potential.
Primary ovarian insufficiency (POI) represents the cessation of ovarian function before age 40 due to follicular depletion or dysfunction. Affecting 1% of women, POI causes infertility and systemic health complications. Current treatments focus on symptom management rather than restoring ovarian function. Mesenchymal stem cells (MSCs) offer promising regenerative potential through paracrine activity, immunomodulation, and tissue repair mechanisms. MSCs from various sources have demonstrated the ability to improve ovarian function, increase follicular survival, and restore hormone production in preclinical models. MSC-derived extracellular vesicles are emerging as cell-free alternatives with similar therapeutic effects. This review examines MSC mechanisms in ovarian restoration, evaluates current evidence, and discusses challenges in clinical translation for POI treatment.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: